Miami Jewish Health

Enrolling Clinical Trials

Marc E Agronin, MD, ***Principal Investigator***

Name of Study: ***EISAI Delphia 201***

Description of Study: This is a Phase II study evaluating the safety, tolerability and efficacy of E2027 in subjects with Dementia with Lewy Bodies.
Indication: Meets criteria for probable Dementia with Lewy Bodies Alzheimer's Disease

Recruiting Participant Age: 50 - 85

Duration of Study: 22 weeks

Name of Study: ***EISAI BAN 2401- G000-301***

Description of Study: This is a Phase III placebo-controlled, double-blind study evaluating the safety, tolerability and efficacy of BAN2401 in subjects with Early Alzheimer's Disease.
Indication: Meets criteria for probable Mild Cognitive Impairment (MCI) – Mild Alzheimer's Disease

Recruiting Participant Age: 50 - 90

Duration of Study: 18 months (optional open label extension)

Name of Study: ***MIND Study*****- Long-Term Nicotine Treatment of Mild Cognitive Impairment. Academia** ***Study, Funded by the National Institute on Aging (NIA) and conducted by Vanderbilt University and University of Southern California***

Description of Study: The purpose of the Memory Improvement through Nicotine Dosing (MIND) phase II study, is to determine whether nicotine (in patch form) improves memory and functioning in adults diagnosed with MCI

Indication: Mild Cognitive Impairment or Memory Loss

Recruiting Participant Age: 55years +

Duration of Study: 2 years

Name of Study: ***Longeveron***

Description of Study: This is a Phase I study to evaluate the safety and potential efficacy of Longeveron Allogenic Human Mesenchymal Stem Cell (LMSC) Infusion versus placebo in patients with Alzheimer's Disease.
Indication: Mild Alzheimer's Disease

Recruiting Participant Age: 55 - 80

Duration of Study: 52 weeks after infusion with LMSCs

Name of Study: *Dronabinol– Johns Hopkins*

Description of Study: This is a Phase II placebo-controlled, double-blind randomized clinical trial of Dronabinol in patients with severe Agitation – AD.
Indication: Alzheimer's Disease with Agitation

Recruiting Participant Age: 60 - 90

Duration of Study: 3 weeks

Name of Study: *S-CitAD – Johns Hopkins*

Description of Study: This is a Phase II placebo-controlled, masked, study assessing the safety, tolerability and efficacy of Escitalopram for Agitation in Alzheimer's Disease.in subjects not receiving Memantine treatment.
Indication: Alzheimer's Disease with Agitation

Recruiting Participant Age: 18 years +

Duration of Study: approximately 24 weeks (12-week treatment period)

Name of Study: *Genentech – Lauriet GN40040*

Description of Study: This is a Phase II placebo-controlled, double –blind randomized, study assessing the safety and efficacy of MTAU9937A in subjects with Moderate Alzheimer's Disease.
Indication: Moderate Alzheimer's Disease

Recruiting Participant Age: 50 - 85

Duration of Study: approximately 48 weeks (optional open label extension)

If you are interested in participating or learning more about our clinical trials, please call 305-514-8710

EDiaz1@miamijewishhealth.org **RCastaneda@miamijewishhealth.org**